{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:50:44Z","timestamp":1792176644333,"version":"4.4.0"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T00:00:00Z","timestamp":1518393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pain"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Antiepileptic drugs are the first\u2010line treatment for trigeminal neuralgia (<jats:styled-content style=\"fixed-case\">TN<\/jats:styled-content>). Carbamazepine and oxcarbazepine are the most studied with well\u2010known efficacy. Eslicarbazepine acetate is a third\u2010generation antiepileptic drug that has not previously been evaluated for the treatment of <jats:styled-content style=\"fixed-case\">TN<\/jats:styled-content>. We aim to assess the efficacy, tolerability and safety of eslicarbazepine for <jats:styled-content style=\"fixed-case\">TN<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design and Methods<\/jats:title><jats:p>Retrospective, open\u2010label, multicentric, intention\u2010to\u2010treat study. We included patients older than 18\u00a0years who met the <jats:styled-content style=\"fixed-case\">ICHD<\/jats:styled-content>\u20103 beta diagnostic criteria for <jats:styled-content style=\"fixed-case\">TN<\/jats:styled-content>. We evaluated the variation of intensity and frequency of pain paroxysms before and after treatment with eslicarbazepine. Secondary objectives assessed were tolerability and safety of eslicarbazepine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eighteen patients were included, 15 women, mean age 65.2\u00a0years old, mean follow\u2010up 21.1\u00a0months. The mean number of drugs tested before eslicarbazepine was 2; 10 patients used eslicarbazepine as monotherapy. After the treatment with ESL, the median of pain intensity improved from 9.5 to 2.5 (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.001) and the median of pain paroxysms frequency improved from 70 episodes per week to 0.37 (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.001). Responder rate was 88.9%; 44.4% became asymptomatic after treatment. Sixty\u2010one per cent of patients presented some adverse event; four patients discontinued eslicarbazepine for this reason. Despite this, 16 patients (88.9%) noticed a good subjective tolerance to eslicarbazepine. The retention rate at 6\u00a0months was 77.8% and at 12\u00a0months 61.1%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our study supports the hypothesis that eslicarbazepine acetate is an effective, safe and well\u2010tolerated treatment for the treatment of <jats:styled-content style=\"fixed-case\">TN<\/jats:styled-content>. Further studies are warranted to corroborate these results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Significance<\/jats:title><jats:p>Eslicarbazepine acetate has shown to be an effective, safe and well\u2010tolerated drug for <jats:styled-content style=\"fixed-case\">TN<\/jats:styled-content>. This is the first study that evaluated the efficacy of this drug on <jats:styled-content style=\"fixed-case\">TN<\/jats:styled-content> in humans.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ejp.1192","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T12:56:47Z","timestamp":1516885007000},"page":"1080-1087","source":"Crossref","is-referenced-by-count":43,"title":["Assessment of efficacy and safety of eslicarbazepine acetate for the treatment of trigeminal neuralgia"],"prefix":"10.1002","volume":"22","author":[{"given":"A.","family":"Sanchez\u2010Larsen","sequence":"first","affiliation":[{"name":"Neurology Department Complejo Hospitalario Universitario de Albacete Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sopelana","sequence":"additional","affiliation":[{"name":"Neurology Department Complejo Hospitalario Universitario de Albacete Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Diaz\u2010Maroto","sequence":"additional","affiliation":[{"name":"Neurology Department Complejo Hospitalario Universitario de Albacete Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Perona\u2010Moratalla","sequence":"additional","affiliation":[{"name":"Neurology Department Complejo Hospitalario Universitario de Albacete Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gracia\u2010Gil","sequence":"additional","affiliation":[{"name":"Neurology Department Complejo Hospitalario Universitario de Albacete Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Garc\u00eda\u2010Mu\u00f1ozguren","sequence":"additional","affiliation":[{"name":"Neurology Department Grupo Hospitales de Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Palaz\u00f3n\u2010Garc\u00eda","sequence":"additional","affiliation":[{"name":"Neurology Department Complejo Hospitalario Universitario de Albacete Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Segura","sequence":"additional","affiliation":[{"name":"Neurology Department Complejo Hospitalario Universitario de Albacete Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,12]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"pii: S0213\u20104853","article-title":"Eslicarbazepine acetate for neuropathic pain, headache, and cranial neuralgia: Evidence and experience","volume":"16","author":"Alc\u00e1ntara Montero A.","year":"2017","journal-title":"Neurologia"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03519.x"},{"issue":"6","key":"e_1_2_7_4_1","first-page":"260","article-title":"The effects of eslicarbazepine, R\u2010licarbazepine, oxcarbazepine and carbamazepine on ion transmission Cav3.2 channels","volume":"52","author":"Brady K.","year":"2011","journal-title":"Epilepsia"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102415620252"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02185.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002840"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2002.96.3.0532"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1129-2377-15-34"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12242"},{"key":"e_1_2_7_12_1","first-page":"639","article-title":"Experience with eslicarbazepine acetate as treatment for painful diabetic neuropathy","volume":"31","author":"Garcia\u2010Escriv\u00e0 A.","year":"2016","journal-title":"Neurologia"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03605.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000326598.83183.04"},{"issue":"6","key":"e_1_2_7_15_1","first-page":"257","article-title":"Inhibitory effects of eslicarbazepine acetate and its metabolites against neuronal voltage\u2010gated sodium channels","volume":"52","author":"Hebeisen S.","year":"2011","journal-title":"Epilepsia"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2015.06.013"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12441"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP46119"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411424619"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200201000-00004"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2009.08.037"},{"issue":"6","key":"e_1_2_7_22_1","first-page":"258","article-title":"The effects of eslicarbazepine, R\u2010licarbazepine and carbamazepine on ion transmission through Kv7.2 channels","volume":"52","author":"Soares\u2010da\u2010Silva P.","year":"2011","journal-title":"Epilepsia"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.124"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2016.00131"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000000953"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002720"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2014.04.014"},{"key":"e_1_2_7_28_1","first-page":"CD001133","article-title":"Anticonvulsant drugs for acute and chronic pain","volume":"3","author":"Wiffen P.","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102412441721"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2013.03.016"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S57409"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1238"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30005-4"}],"container-title":["European Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejp.1192","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejp.1192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T18:04:28Z","timestamp":1695492268000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ejp.1192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1002\/ejp.1192"],"URL":"https:\/\/doi.org\/10.1002\/ejp.1192","archive":["Portico"],"relation":{},"ISSN":["1090-3801","1532-2149"],"issn-type":[{"value":"1090-3801","type":"print"},{"value":"1532-2149","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,12]]}}}